Sentence: Combination of ibrutinib and ublituximab ( n = 64 ) had an ORR of 78 % ( CR 7 % ) in a phase 3 study .
Drug combination annotation:
[{'class': 'POS', 'spans': ['ibrutinib', 'ublituximab'], 'is_context_needed': True}]